[A17-50] Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V

Last updated 02.01.2018

Project no.:

Commission awarded on 29.09.2017 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy

Result of dossier assessment:

Patients for whom treatment with docetaxel, pemetrexed or nivolumab is indicated: indication of a major added benefit (PD-L1 high) or non-quantifiable added benefit (PD-L1 low) Other patients: added benefit not proven.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form